Ambrx, Inc. and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate for Breast Cancer
6/17/2013 11:16:28 AM
More...
|
Ambrx, Inc. and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate for Breast Cancer
6/17/2013 8:47:25 AM
More...
|
Bristol-Myers Squibb Company (BMY) Partners Again With Ambrx, Inc. in Up to $112 Million and Up ADC Collaboration
5/3/2013 7:19:51 AM
More...
|
Astellas Pharma Inc. (YPH.BE) Signs $300 Million Cancer Pact With Ambrx, Inc.
4/5/2013 7:49:05 AM
More...
|
Ambrx, Inc. Appoints Lawson Macartney, Ph.D., DVM, CEO
1/7/2013 6:48:52 AM
More...
|
Merck & Co., Inc. (MRK) Bets Up to $303 Million on Ambrx, Inc.'s "Smart Bomb" Antibodies
6/18/2012 6:38:52 AM
More...
|
Bristol-Myers Squibb Company (BMY) and Ambrx, Inc. Announce $24 Million Collaboration for Novel Biologics Programs in Diabetes and Heart Failure
9/22/2011 6:54:12 AM
More...
|
Ambrx, Inc. to Present Data from Antibody Drug Conjugate Program at Upcoming Scientific Conferences
6/22/2011 8:53:42 AM
More...
|
Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx, Inc.
5/25/2011 10:33:25 AM
More...
|
Ambrx, Inc. CEO Steve Kaldor Departs
7/13/2010 8:02:07 AM
More...
|
|